Donor-derived cell-free DNA test for organ transplant monitoring.

Determination of the level of Circulating Cell-Free DNA derived from the donor in transplant recipients. The relative quantification of the level of Circulating Cell-Free DNA derived from the donor can help improve transplant surveillance. Circulating Cell-Free DNA is fragmented DNA in the bloodstream that comes from cells undergoing injury and dying. When transplant injury occurs, the Circulating Cell-Free DNA derived from the donor (dd-cfDNA) increases in the blood. AlloSeq cfDNA measures the Circulating Cell-Free DNA derived from the donor (dd-cfDNA) using low DNA input, next-generation sequencing (NGS) technology and optimized analysis to improve transplant surveillance.

Revolutionizing Chimerism Monitoring

The latest innovation in chimerism testing offers streamlined workflow with best-in-class sensitivity.

Chimerism changes after hematopoietic cell transplant can be an early indication of relapse.*

Key Features:

• A NGS-based chimerism testing solution that is able to determine the relative contribution of up to 3 genomes in a single sample, i.e., up to two donors per recipient
• A kit-based test that offers high-quality data with a recommended input of 10 ng of gDNA and up to 96 samples per batch
• - One-step multiplex assay that utilizes 202 SNPs across all autosomal chromosomes to differentiate between recipient and donor(s) gDNA

- A highly sensitive, scalable assay with time-saving automated analysis software